February 2021 in “Медико-фармацевтический журнал "Пульс"” This study explored the roles of β-catenin and sclerostin levels in patients with androgenic and alopecia areata, analyzing their potential involvement in the hair follicle morphogenesis and Wnt signaling pathway.
81 citations
,
July 2012 in “Translational Psychiatry” In this pilot study, no significant differences were observed between memantine and placebo groups in young adults with Down syndrome on the primary memory outcomes, but some improvement was noted in a secondary measure.
24 citations
,
January 2003 in “Journal of Investigative Dermatology” In this study, a synthetic antagonist of the p75 neurotrophin receptor was found to significantly inhibit hair follicle regression in murine skin cultures, suggesting a potential role in treating hair disorders characterized by premature catagen entry.
1 citations
,
October 1935 in “Nature” Potassium iodide prevents hair loss and reduces toxicity from thallium acetate.
68 citations
,
November 2015 in “The Journal of Allergy and Clinical Immunology” In this study, three patients with extensive alopecia areata showed varying degrees of hair regrowth after 20 weeks of treatment with ustekinumab, a cytokine-targeting therapy.
51 citations
,
February 2010 in “Analytical and Bioanalytical Chemistry” Researchers developed a method to detect hormone-blocking drugs in wastewater and found them in Beijing's sewage, suggesting they can survive sewage treatment.
47 citations
,
October 2016 in “Molecular and Cellular Endocrinology” This study found that DKK1 and WNT10b are paracrine factors that modulate hair follicle stem cell differentiation inhibition, contributing to androgenetic alopecia by affecting Wnt signaling in androgen-sensitive dermal papilla cells after dihydrotestosterone stimulation.
27 citations
,
January 1984 in “Pharmacology & Therapeutics” This review discusses androgen manipulation strategies for conditions like benign prostatic hyperplasia and prostatic carcinoma but reports no new clinical results.
17 citations
,
August 2007 in “Bioorganic & Medicinal Chemistry Letters” This study found that a specific amino-pyridine compound showed potent androgen receptor antagonist activity, stimulating hair growth in mice and reducing sebum production in a hamster model.
9 citations
,
July 2014 in “Experimental Dermatology” This study suggests that while PTH rP initially seemed to shorten the hair cycle by transitioning hair follicles from anagen to catagen, more relevant models indicate it ultimately accelerates and stimulates hair growth.
8 citations
,
October 2016 in “Journal of Investigative Dermatology” This study found that using mineralocorticoid receptor antagonists with glucocorticoid therapy improved wound healing in diabetic animals by enhancing keratinocyte proliferation and epithelialization.
7 citations
,
June 2010 in “Bioorganic & medicinal chemistry letters” This study found that aminomethylpyrazole compound 10l inhibited hair growth in a mouse model and showed a low risk for photo-irritation, though it was slightly less effective than eflornithine.
5 citations
,
September 2011 in “Bioorganic & Medicinal Chemistry Letters” This study identified pantolactam based compounds as effective topical antagonists of the androgen receptor, reducing sebum components in a hamster model.
4 citations
,
January 1982 in “Neuroendocrinology” This study found that pimozide, d-butaclamol, and pituitary pars intermedia grafts darken hair color in agouti C3H Avy mice, suggesting dopaminergic inhibition influences peptide-controlled hair color cycling.
2 citations
,
November 2017 in “Elsevier eBooks” This article discusses the role of the androgen receptor in regulating development and homeostasis, and reviews treatment approaches for conditions related to hormone imbalances, without reporting new clinical findings.
1 citations
,
January 2019 in “Skin Pharmacology and Physiology” This study found that inhibiting mineralocorticoid receptor signaling in female human hair follicles may promote hair growth by extending the anagen phase and encouraging keratinocyte proliferation.
1 citations
,
December 2011 in “Arzneimittelforschung” This study found that the compound 9,11-dehydrocortexolone 17alpha-butyrate (CB-03-04) showed strong local antiandrogenic activity in animal models, suggesting potential for treating prostate conditions.
In this study, the researchers reported that the optimized compound 39 demonstrated potent AR antagonism and favorable pharmacokinetics in a hair-growth mouse model, achieving similar efficacy to pyrilutamide with faster onset and preserved safety, offering promise for next-generation topical AR antagonist development.
This study found that the optimized topical AR antagonist 39, derived from 14-P1, demonstrated potent AR antagonism and comparable efficacy to pyrilutamide in a hair-growth mouse model, with a faster onset and favorable safety profile.
In this study, researchers optimized the soft drug AR antagonist 14-P1 to create candidate 39, which demonstrated effective AR antagonism and safety in a hair-growth mouse model, showing similar efficacy to pyrilutamide but with quicker onset and a lower risk of systemic toxicity.
In a hair-growth mouse model, this study reported that the novel AR antagonist candidate 39, derived from structural optimization of 14-P1, achieved similar efficacy to pyrilutamide with faster response and maintained safety, demonstrating potent AR antagonism and favorable pharmacokinetics with lower systemic toxicity risk.
This study found that the optimized AR antagonist compound 39 showed potent hair growth activity with improved safety in mice, suggesting potential for better topical treatments for androgenetic alopecia.
In a mouse hair-growth model, this study found that the optimized compound 39 matched the efficacy of pyrilutamide for androgenic alopecia, with faster response and maintained safety, suggesting it as a promising topical AR antagonist with reduced systemic toxicity risk.
In this study, a dual soft drug design strategy improved the AR antagonist candidate 39, showing potent AR antagonism and good safety in a mouse hair-growth model, with similar efficacy to pyrilutamide but faster response.
This study found that the optimized AR antagonist candidate 39, in a hair-growth mouse model, achieved similar efficacy to pyrilutamide with faster onset and favorable safety, suggesting a promising approach for developing topical treatments with low systemic toxicity for androgenetic alopecia.
This study reports that the newly optimized AR antagonist 39 demonstrated effective hair growth and safety in a mouse model of androgenetic alopecia, showing comparable efficacy to pyrilutamide with faster response and favorable pharmacokinetics, due to innovative structural design and dual metabolic inactivation strategy.
July 2026 in “Journal of Medicinal Chemistry” In this study, candidate compound 39 demonstrated potent androgen receptor antagonism and faster hair-growth efficacy in a mouse model compared to pyrilutamide, while maintaining favorable safety and pharmacokinetic profiles, suggesting potential for topical use in androgenic alopecia.
October 2023 in “Scientific reports” In this study, researchers found that the synthetic stress hormone dexamethasone caused opposite effects on hair growth-related proteins, reducing SFRP2 and increasing SFRP3, which respectively stimulate and inhibit hair follicle cell proliferation in human dermal papilla cells.
August 2016 in “Journal of Investigative Dermatology” This study found that dihydrotestosterone alters the balance of Wnt pathway regulators in dermal papilla cells, hindering hair follicle stem cell differentiation and contributing to hair follicle miniaturization.